Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
10 lutego 2017 zaktualizowane przez: AbbVie
This post marketing observational study (PMOS) was conducted in Japan during the 2013-2014 and 2014-2015 Respiratory Syncytial Virus (RSV) seasons to assess the safety and effectiveness of palivizumab for the prevention of serious lower respiratory tract infection caused by RSV in participants 24 months of age and under, who have an immunocompromised medical condition (e.g., combined immunodeficiency disease, antibody deficiency, or other types of immunodeficiency; HIV infection; recovering from organ or bone marrow transplantation; on chemotherapy; on high-dose corticosteroid therapy; on immunosuppressants) or who have Down syndrome.
Przegląd badań
Status
Zakończony
Szczegółowy opis
Palivizumab was prescribed according to the local label and independently of the decision to enroll participants in the study.
Palivizumab was administered monthly throughout the Respiratory Syncytial Virus (RSV) infection seasons via intramuscular injection at a dose of 15 mg/kg of body weight.
Survey forms were collected after the observation period.
The number of adverse events and the frequency of hospitalizations due to RSV infections in surveyed participants were assessed to evaluate the safety and effectiveness of palivizumab.
Typ studiów
Obserwacyjny
Zapisy (Rzeczywisty)
312
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
Nie starszy niż 2 lata (Dziecko)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
Single-arm, Multi-center, Prospective Cohort
Opis
Inclusion Criteria:
- Availability of a parent or legal guardian who was capable and willing to give written informed consent for his/her newborn, infant or young child to participate in the study
- Participants receiving palivizumab for prevention of serious lower respiratory tract disease caused by RSV infection
Newborns, infants, or young children 24 months of age and under who have an immunocompromised medical condition:
- combined immunodeficiency, (severe combined immunodeficiency, X-linked hyper-immunoglobulin M (IgM) syndrome, etc.), antibody deficiency (X-linked agammaglobulinemia,common variable immunodeficiency, non-X-linked hyper-IgM syndrome,etc.) or other immunodeficiency (Wiskott-Aldrich syndrome, etc.)
- acquired T cell dysfunction ( such as human immunodeficiency virus (HIV) infection etc.)
- history of past organ transplantation
- history of past bone marrow transplantation
- receiving immunosuppressive chemotherapy
- receiving systemic high-dose corticosteroid therapy (prednisone equivalents ≥ 0.5 mg/kg/every other day, other than inhaler or topical use), or
- receiving other immunosuppressive therapy (azathioprine, methotrexate, mizoribine, mycophenolate mofetil, cyclophosphamide, cyclosporine, tacrolimus, cytokine inhibitors, etc.)
- receiving biologics (including cytokine inhibitors)
- Others (nephrotic syndrome, chronic peritoneal dialysis, hemodialysis)
- Newborns, infants, or young children age of 24 months and under who have Down syndrome without a current hemodynamically significant Congenital Heart Disease. The participant must have had an experience with persistent respiratory symptoms or regular outpatient treatment due to respiratory tract infection prior to current RSV season.
Exclusion criteria:
- Participants included in the Contraindications section of the package insert
- Participants with known hypersensitivity to the ingredients of palivizumab
- Participants with a known positive RSV infection before hospitalization
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Immunocompromised children
Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants With Adverse Events
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with their treatment.
Adverse events were documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
|
Number of Participants With Serious Adverse Events
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
A serious adverse event was defined as any untoward medical occurrence in a participant that the investigator believed to be causally related to the study treatment and met at least one of the following criteria: death, life-threatening, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity, or important medical event requiring medical or surgical intervention to prevent serious outcome.
Serious adverse events were documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
|
Number of Participants With Adverse Drug Reactions
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with their treatment.
If a causal relationship with palivizumab was: "Related", "Causality cannot be ruled out", or "Not assessable" as determined by the investigator, it was classified as an adverse drug reaction (ADR).
An AE was considered a serious adverse event (SAE) and a serious adverse drug reaction (SADR) if the severity of the AE or ADR was any one of the following, as determined by the investigator: "Death", "Life-threatening condition", "Hospitalization or prolonged hospitalization", "Persistent or significant disability", or "Other medically important condition".
Information about AEs and ADRs was documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Lower Respiratory Tract Infection (LRI) Score During the Study
Ramy czasowe: From the first administration of palivizumab up to the last administration of palivizumab, up to 36 weeks
|
The Lower Respiratory Tract Infection (LRI) Score ranged from 0 (well or baseline); 1 (Upper Respiratory tract Infection [URI]), mild); 2 (LRI); 3 (LRI, moderate); 4 (LRI, severe) to 5 (Respiratory Failure).
Components of the score included respiratory rate per minute, oxygen saturation, and physical findings of LRI.
LRI scores were documented on the case report form (CRF).
|
From the first administration of palivizumab up to the last administration of palivizumab, up to 36 weeks
|
|
Number of Participants Hospitalized Due to Respiratory Syncytial Virus (RSV) Infection
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
Hospitalization due to RSV infection or the presence/absence of positive RSV antigen test results during hospitalization was documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
|
Mean Hospitalization Length Due to Respiratory Syncytial Virus (RSV) Infection
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
The date of hospitalization due to RSV infection and the date of hospital discharge were documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
|
Number of Hospitalized Participants Requiring Respiratory Support
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
The presence/absence of respiratory support, (oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, and other mechanical respiratory support or Intensive Care Unit admission) the start and end dates of respiratory support, and the dates of hospitalization and discharge were documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
|
Mean Duration of Respiratory Support
Ramy czasowe: From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
The presence/absence of respiratory support (oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, and other mechanical respiratory support or Intensive Care Unit admission) and the start and end dates of respiratory support were documented on the case report form (CRF).
|
From the first administration of palivizumab to 30 days after the last administration of palivizumab, up to 44 weeks
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Śledczy
- Dyrektor Studium: Osamu Mikami, MD, PhD, AbbVie GK.
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Przydatne linki
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2013
Zakończenie podstawowe (Rzeczywisty)
1 grudnia 2015
Ukończenie studiów (Rzeczywisty)
1 grudnia 2015
Daty rejestracji na studia
Pierwszy przesłany
11 grudnia 2013
Pierwszy przesłany, który spełnia kryteria kontroli jakości
16 grudnia 2013
Pierwszy wysłany (Oszacować)
20 grudnia 2013
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
20 marca 2017
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
10 lutego 2017
Ostatnia weryfikacja
1 lutego 2017
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- P14-296
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIE
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .